BioNTech
Forecast impact
Track in portfolio
Price chart
Description
Company and Business Model
BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Its core products include mRNA-based vaccines, notably the COVID-19 vaccine developed in partnership with Pfizer. Major business segments encompass vaccine development, oncology therapies, and research collaborations. The primary revenue source has been from vaccine sales, particularly during the pandemic, although recent financial reports indicate a significant decline in revenue.
Investment Profile
The investment profile of BioNTech is more aligned with growth investors, given its focus on innovative therapies and potential for future product development. However, the recent decline in revenue and negative earnings per share suggest increased risk, making it less suitable for conservative investors. The stock may appeal to those with a higher risk tolerance looking for long-term growth opportunities.
Fundamental metrics (experimental) Updated: 2026-09-08
- EPS (TTM) — earnings per share for the last 12 months, $
- -6.73
- Revenue QoQ — quarter-over-quarter revenue growth
- -12.0%
- EPS surprise
- -54.3%
- 20d volatility
- 5.5%
- last ex-date
- 2022-06-02
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-08-29 | Hold | Sell | Weak fundamentals and negative momentum raise significant risk. |
| 2026-08-15 | Sell | Hold | Weak fundamentals and high risk limit upside potential. |
| 2026-05-12 | Hold | Sell | scenario_deterioration |
| 2026-05-08 | — | Hold | Weak fundamentals and negative momentum signal high risk. |
| 2026-05-08 | Hold | Hold | Компания демонстрирует значительное снижение выручки и отрицательный EPS, что указывает на финансовые трудности. Текущие тренды и высокая волатильность делают инвестиции в BioNTech рискованными. |
| 2026-04-17 | Sell | Hold | Компания испытывает значительное снижение выручки и отрицательный EPS, что указывает на высокие риски. Однако недавний рост цены акций может свидетельствовать о восстановлении интереса инвесторов. |
| 2026-03-22 | Hold | Sell | scenario_deterioration |
| 2026-03-11 | — | Hold | Компания испытывает значительное падение цен на акции и нестабильность в финансовых показателях, что указывает на высокие риски для инвесторов. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-08 | BMO Capital | Update | — → 105 | 103.76 |
| 2026-08-31 | Canaccord Genuity | Target Lowered | 142 → 136 | 102.075 |
| 2026-08-05 | Canaccord Genuity | Target Raised | 138 → 142 | 91.35 |
| 2026-07-08 | Morgan Stanley | Target Lowered | 126 → 119 | 94.29 |
| 2026-05-27 | UBS | Rating Upgraded | — → 135 | 92.25 |
| 2026-05-21 | Bernstein | Update | — → 96 | 90.93 |
| 2026-05-06 | Canaccord Genuity | Target Lowered | 171 → 158 | 95.5 |
| 2026-04-10 | Morgan Stanley | Target Raised | 125 → 126 | 93.381 |
| 2026-03-11 | BMO Capital | Target Lowered | — → 128 | 90.52 |
| 2026-03-10 | Jefferies | Target Lowered | — → 138 | 83.89 |
| 2026-03-10 | Truist Financial | Update | — → 155 | 83.89 |
| 2026-03-10 | Morgan Stanley | Target Lowered | — → 128 | 83.89 |
| 2026-02-02 | Leerink Partners | Rating Downgraded | — → 113 | 113.75 |
| 2026-01-16 | Goldman Sachs | Rating Upgraded | — → 142 | 106.07 |
| 2025-12-11 | Berenberg Bank | Target Raised | 150 → 155 | 95.68 |
| 2025-12-11 | H.C. Wainwright | Update | — → 140 | 96.91 |
| 2025-11-03 | Morgan Stanley | Target Raised | 131 → 134 | 103.955 |
News Page 1 of 1
Nothing yet